Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Depression in Young Women: Often There, Often Overlooked

Published: Fri, 20 Apr 2018 10:15:17 EDT
Dr. Arefa Cassoobhoy highlights a gap in treating depression in young women.
Medscape Internal Medicine

Marijuana and the Developing Brain: Current State of Evidence

Published: Fri, 20 Apr 2018 10:06:34 EDT
What do we know about the effect of marijuana on the adolescent brain?
Medscape Pediatrics

Delabeling for Penicillin Allergy Found Safe in Children

Published: Fri, 20 Apr 2018 08:02:52 EDT
Children with low-risk penicillin allergy symptoms who tested negative for penicillin allergy tolerated penicillin without serious adverse or allergic reactions during the following year, a study found.
Medscape Medical News

CMS Should Have Required a Randomized Trial of F1CDx

Published: Fri, 20 Apr 2018 12:00:00 EDT
Authors give five reasons why CMS should have refrained from coverage of a 324-gene panel offered by Foundation Medicine in the absence of a randomized trial.
Annals of Oncology
Displaying results 17-20 (of 20)
 1 - 2 - 3 - 4 - 5 


Johnson & Johnson says it has 15% more to splash on R&D thanks to tax cuts. Will we see more pipeline plays?

Published: Tue, 17 Apr 2018 11:14:14 +0000
Share buybacks have been the name of the game for a few years now as M&A went through a quiet patch, but with deals ramping up in 2018, Johnson & Johnson says it's boosting its R&D budget over the coming years. Will the Big Pharma be looking to beef up its pipeline?

Phase 1 data backs Cyclacel’s plans for CDK2/9 inhibitor

Published: Mon, 16 Apr 2018 13:47:56 +0000
Just over a year ago, Cyclacel was hit by a late-stage failure in leukemia that sent its shares into a tailspin and pushed an early-stage CDK inhibitor into the spotlight as its most promising candidate. Now, that CDK drug has shown it can stabilize disease in advanced cancers and is ready to be twinned with AbbVie's leukemia drug Venclexta in phase 2.

Antifungal ‘prodrug’ shows promise in bladder cancer: AACR

Published: Mon, 16 Apr 2018 13:11:10 +0000
When bladder cancer progresses to stage 2, invading the muscle, survival drops to 63% at best. A compound that transforms into the antifungal drug ciclopirox as the body metabolizes it inhibits the progression of bladder cancer in mouse models of the disease.

Apitope preps Graves’ disease drug for phase 2 after positive trial

Published: Mon, 16 Apr 2018 11:52:01 +0000
Apitope has taken a step closer to developing the first new treatment option for thyroid disorder Graves’ disease in decades after posting positive results in a first-in-human trial of its ATX-GD-59 antibody.
Displaying results 21-24 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy